5-溴-2-氯甲基苯并呋喃 | 38220-78-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 5-溴-2-氯甲基苯并呋喃
• 中文别名: 2-(二甲基氨基)-3-喹啉甲醛；5-溴-2-(氯甲基)苯并[B]呋喃
• 英文名称: 5-bromo-2-(chloromethyl)benzofuran
• 英文别名: 5-Bromo-2-chloromethylbenzofuran；5-bromo-2-(chloromethyl)-1-benzofuran
• CAS: 38220-78-9
• 化学式: C₉H₆BrClO
• 分子量: 245.503
• InChiKey: IGVKTJSZEQNSNH-UHFFFAOYSA-N

物化性质

• 熔点：
  62-64°C
• 沸点：
  309.7±27.0 °C(Predicted)
• 密度：
  1.634±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2932999099
• 储存条件：
  室温

SDS

Name:	tert-Butyl 4-(3-formylbenzyl)tetrahydro-1(2H)-pyrazinecarboxylate Material Safety Data Sheet
Synonym:	None Known
CAS:	38220-78-9

Section 1 - Chemical Product MSDS Name:tert-Butyl 4-(3-formylbenzyl)tetrahydro-1(2H)-pyrazinecarboxylate Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
38220-78-9	tert-Butyl 4-(3-formylbenzyl)tetrahydr	97+%	unlisted

Hazard Symbols: C
Risk Phrases: 22 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Harmful if swallowed. Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 38220-78-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C17H24N2O3
Molecular Weight: 304.39

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
n dioxide, potassium nitrate), reducing agents (strong, e.g. aluminum carbide, chlorosilane, hydrogen phosphide, lithium hydride), water reactive substances (e.g. acetic anyhdride, alkyl aluminum chloride, calcium carbide, ethyl dichlorosilane),.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 38220-78-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
tert-Butyl 4-(3-formylbenzyl)tetrahydro-1(2H)-pyrazinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.*
Hazard Class: 8
UN Number: 3259
Packing Group: III
IMO
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing Group: III
RID/ADR
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 22 Harmful if swallowed.
R 34 Causes burns.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 38220-78-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 38220-78-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 38220-78-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-2-氯甲基苯并呋喃 在 chromium chloride 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 以47 %的产率得到
  参考文献：
  名称：

  3,3-二取代吲哚酮类化合物及其用途

  摘要：

  本发明3,3‑二取代吲哚酮类化合物及其用途提供了式(I)化合物，或其药学上可接受的盐、同位素变体、互变异构体、立体异构体、前药、多晶型、水合物或溶剂合物。本发明还提供了所述化合物的制备方法、包含所述化合物的药物组合物，以及所述化合物在预防和治疗相关癌症，例如乳腺癌、卵巢癌、子宫癌、宫颈癌或子宫内膜癌等中的作用。

  公开号：

  CN115490673A
• 作为产物：
  描述：

  (5-溴苯并呋喃)-2-羧酸乙酯 在 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 2.0h， 生成 5-溴-2-氯甲基苯并呋喃
  参考文献：
  名称：

  卤代甲基杂芳烃的铬催化不对称脱芳香化加成反应

  摘要：

  铬催化实现了包括苯并呋喃和苯并噻吩在内的卤代甲基芳烃的首次不对称脱芳香化加成反应。在温和的反应条件下，各种醛可用作合适的亲电子试剂。分子的复杂性以高度非对映和对映选择性的方式迅速增加。

  DOI：

  10.1021/acs.orglett.6b00559

文献信息

• [EN] TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS<br/>[FR] TRAITEMENT OU PROPHYLAXIE D'ÉTATS PROLIFÉRATIFS
  申请人：UNIV DUNDEE

  公开号：WO2010125350A1

  公开（公告）日：2010-11-04

  The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

  该发明涉及用于治疗或预防癌症和其他增殖性疾病的新化合物，例如这些疾病的特征是细胞表达细胞色素P450 1B1（CYP1B1）及其等位基因变体。该发明还提供包含一种或多种此类化合物的药物组合物，用于医学治疗，例如用于治疗或预防癌症或其他增殖性疾病，以及用于治疗人类或非人类动物患者的癌症或其他疾病的方法。该发明还提供用于识别用于治疗或预防癌症和其他增殖性疾病的新化合物的方法，例如这些疾病的特征是细胞表达CYP1B1及其等位基因变体。该发明还提供一种用于确定该发明中化合物治疗癌症的疗效的方法。
• [EN] SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C<br/>[FR] INHIBITEURS DE CATHEPSINE C DE TYPE (CYANO-MÉTHYL)-AMIDES D'ACIDE 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIQUE SUBSTITUÉ
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014140078A1

  公开（公告）日：2014-09-18

  This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides of formula (1) and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

  这项发明涉及式（1）的2-Aza-bicyclo[2.2.1]庚烷-3-羧酸（氰基甲基）酰胺及其作为Cathepsin C抑制剂的用途，含有该化合物的药物组合物，以及将其用作治疗和/或预防与二肽基肽酶I活性相关的疾病，例如呼吸道疾病的药物的方法。
• TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS
  申请人：Everett Steven Albert

  公开号：US20120190639A1

  公开（公告）日：2012-07-26

  The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

  本发明涉及新型化合物，用于治疗或预防癌症和其他增生性疾病，例如其细胞表达细胞色素P450 1B1（CYP1B1）及其等位基因变异的疾病。本发明还提供了含有一种或多种这样的化合物的制药组合物，用于医学治疗，例如治疗癌症或其他增生性疾病的预防或治疗，以及用于治疗人类或非人类动物患者的癌症或其他疾病的方法。本发明还提供用于鉴定用于治疗或预防表达CYP1B1及其等位基因变异的细胞的癌症和其他增生性疾病的新型化合物的方法。本发明还提供了一种用于确定本发明的化合物在治疗癌症方面的功效的方法。
• Treatment or prophylaxis of proliferative conditions
  申请人：University Court of The University of Dundee

  公开号：EP2857018A1

  公开（公告）日：2015-04-08

  The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1 B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

  本发明涉及用于治疗或预防癌症和其他增殖性疾病的新型化合物，这些癌症和其他增殖性疾病的特征是细胞表达细胞色素P450 1 B1（CYP1B1）及其等位变体。本发明还提供了包含一种或多种此类化合物的药物组合物，用于医学治疗，例如用于治疗预防癌症或其他增殖性病症，以及用于治疗人类或非人类动物患者的癌症或其他病症的方法。本发明还提供了鉴定新型化合物的方法，这些化合物可用于治疗例如以表达 CYP1 B1 及其等位基因变体的细胞为特征的癌症和其他增殖性疾病的预防。本发明还提供了一种确定本发明化合物治疗癌症疗效的方法。
• Alkene carboamination/oxidative denitrogenation of 3-allyl-3-hydrazinylindolin-2-ones: one-pot entry to spirocyclopropyloxindoles
  作者：Marco Manenti、Tommaso Villa、Giovanni Macetti、Alessandra Silvani

  DOI：10.1039/d3ob02115g

  日期：2024.3.6

  A one-pot protocol, consisting of a Pd-catalysed carboamination reaction, followed by N-deprotection and oxidative denitrogenation, has been developed for the synthesis of diversely substituted spirocyclopropyloxindoles, in yields up to 73% and with diastereoselectivity close to 1 : 1. Readily accessible starting materials, mild reaction conditions, an easy to operate one-pot procedure and good functional

  已开发出一锅法，包括 Pd 催化的碳胺化反应，然后进行N-脱保护和氧化脱氮，用于合成多种取代的螺环丙基羟吲哚，收率高达 73%，非对映选择性接近 1:1。易于获得的起始原料、温和的反应条件、易于操作的一锅法和良好的官能团耐受性使该转化成为合成取代螺环丙基羟吲哚的通用工具。该方案成功地在克级上发挥作用，并允许分别访问两种非对映异构体。提出了一个合理的机制，并对所得产物进行了一系列后转化，显示了其显着的合成多功能性。